Barclays
AUTL

Barclays’s Autolus Therapeutics AUTL Stock Holding History

Barclays’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.1K Buy
11,939
+3,865
+48% +$6.06K ﹤0.01% 4591
2026
Q1 		$11.1K Buy
+8,074
New +$12.3K ﹤0.01% 4681
2025
Q4 		– Sell
-7,883
Closed -$12.8K – 5239
2025
Q3 		$12.8K Sell
7,883
-7,917
-50% -$15.5K ﹤0.01% 4999
2025
Q2 		$36K Buy
15,800
+732
+5% +$1.21K ﹤0.01% 4755
2025
Q1 		$23.4K Buy
15,068
+3,209
+27% +$6.51K ﹤0.01% 4770
2024
Q4 		$27.9K Buy
11,859
+10,866
+1,094% +$36.7K ﹤0.01% 4873
2024
Q3 		$3.6K Buy
+993
New +$3.96K ﹤0.01% 5050
2022
Q2 		– Sell
-15,074
Closed -$63K – 5015
2022
Q1 		$63K Buy
+15,074
New +$63.4K ﹤0.01% 4010
2021
Q4 		– Sell
-4
Closed – – 4125
2021
Q3 		$0 Sell
4
-51
-93% -$322 ﹤0.01% 4737
2021
Q2 		$0 Sell
55
-35
-39% -$217 ﹤0.01% 4865
2021
Q1 		$1K Sell
90
-58
-39% -$429 ﹤0.01% 4579
2020
Q4 		$1K Buy
148
+100
+208% +$1.07K ﹤0.01% 4821
2020
Q3 		$1K Hold
48
– – ﹤0.01% 5138
2020
Q2 		$1K Buy
+48
New +$532 ﹤0.01% 5465
2020
Q1 		– Sell
-18
Closed – – 6128
2019
Q4 		$0 Sell
18
-3,177
-99% -$41.6K ﹤0.01% 6334
2019
Q3 		$40K Buy
3,195
+3,150
+7,000% +$41.6K ﹤0.01% 5995
2019
Q2 		$1K Sell
45
-1,455
-97% -$32.5K ﹤0.01% 6821
2019
Q1 		$47K Sell
1,500
-1,961
-57% -$55.8K ﹤0.01% 5919
2018
Q4 		$113K Buy
+3,461
New +$114K ﹤0.01% 4959
2018
Q3 		– Sell
-6,052
Closed -$162K – 7102
2018
Q2 		$162K Buy
+6,052
New +$160K ﹤0.01% 4889

Other funds holding AUTL

MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $26.6M AUM 10.36% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Barclays's AUTL Position: Q2 2026 in Review

Barclays increased its Autolus Therapeutics (AUTL) stake by 48% in Q2 2026, buying an estimated $6.06K and bringing the position to 11,939 shares worth $19.1K. The position accounts for ﹤0.01% of the portfolio, ranked #4591.

Barclays first reported a position in AUTL in Q2 2018 and has held it in 20 quarters since. The position peaked at $162K in Q2 2018. 84 funds tracked by Wall St. Rank hold AUTL as of Q2 2026.

  • Barclays held 11,939 shares of Autolus Therapeutics worth $19.1K as of Q2 2026.
  • Barclays bought 3,865 Autolus Therapeutics shares in Q2 2026, an estimated $6.06K.
  • Autolus Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #4591 holding.
  • Barclays first reported a position in Autolus Therapeutics in Q2 2018 and has held it in 20 quarters since.
  • Barclays's Autolus Therapeutics position peaked at $162K in Q2 2018.
  • 84 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.